Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

The Myelodysplastic Syndromes Channel is supported with funding from Geron (Silver).

VJHemOnc is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.

Share this video  

MDS 2020 | MDS novel agents & HMAs

David Steensma • 5 Mar 2020
MDS 2020
Myelodysplastic Syndromes Azacitidine Decitabine

David Steensma, MD, Dana-Farber Cancer Institute, Boston, MA, discusses the future of hypomethylating agents (HMA) and oral agents as treatment options for myelodysplastic syndromes (MDS). This interview took place at the 2nd Regional Symposium on Myelodysplastic Syndromes (MDS 2020), held in Tel Aviv, Israel.

More from David Steensma

Translating CHIP research into preventive or therapeutic interventions
1:54
Translating CHIP research into preventive or therapeutic interventions
David Steensma • 22 Aug 2025
The association between clonal hematopoiesis and venous thromboembolism
1:08
The association between clonal hematopoiesis and venous thromboembolism
David Steensma • 22 Aug 2025
Updates for 2025 in the field of clonal hematopoiesis
1:06
Updates for 2025 in the field of clonal hematopoiesis
David Steensma • 22 Aug 2025
Novel therapeutic approaches in MPNs: targeting CALR, immune modulation, & JAKi specificity
9:53
Novel therapeutic approaches in MPNs: targeting CALR, immune modulation, & JAKi specificity
David Steensma • 27 Jun 2025

Related Videos

The ACCESS study: impact of HLA disparity on transplant outcomes in patients receiving MMUD grafts
2:53
The ACCESS study: impact of HLA disparity on transplant outcomes in patients receiving MMUD grafts
David Steensma • 6 Dec 2025
Practice-changing highlights in MDS from ASH 2025: the VERONA trial and triplet combinations
1:07
Practice-changing highlights in MDS from ASH 2025: the VERONA trial and triplet combinations
David Steensma • 6 Dec 2025
Outcomes of HMA plus venetoclax in HR-MDS: an analysis from the icMDS validate database
5:58
Outcomes of HMA plus venetoclax in HR-MDS: an analysis from the icMDS validate database
David Steensma • 16 Dec 2025
Olutasidenib with co-targeted therapy in R/R IDH1-mutated myeloid malignancies: Phase II trial
1:30
Olutasidenib with co-targeted therapy in R/R IDH1-mutated myeloid malignancies: Phase II trial
David Steensma • 6 Dec 2025
The content of VJHemOnc is intended for healthcare professionals